To expand patient access to high-cost treatments for rare diseases, the US Food and Drug Administration (FDA) has issued a new regulatory framework for individualized gene therapies alongside efforts by the Centers for Medicare & Medicaid Services (CMS).
According to the FDA, the draft guidance, titled Individualized Human Genome Editing